# Hematopoietic Stem Cell Transplant Survivors Study

> **NCT02652052** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 9 (actual)

## Conditions studied

- Stem Cell Transplant

## Interventions

- **OTHER:** Standard of Care - Observation Only
- **DRUG:** Group 2: Quercetin
- **DRUG:** Group 2: Dasatinib

## Key facts

- **NCT ID:** NCT02652052
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-01
- **Primary completion:** 2023-05-23
- **Final completion:** 2023-05-23
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02652052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02652052, "Hematopoietic Stem Cell Transplant Survivors Study". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02652052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*